Palisade Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Palisade Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-119,350	Closed	-$2.16M	–	564
2016 Q3	$2.16M	Buy	+119,350	New	+$2.33M	0.08%	320
2015 Q3	–	Sell	-280,810	Closed	-$9.76M	–	586
2015 Q2	$9.76M	Buy	280,810 +75,080	+36%	+$2.29M	0.25%	147
2015 Q1	$5.34M	Buy	205,730 +25,130	+14%	+$461K	0.13%	265
2014 Q4	$2.33M	Buy	+180,600	New	+$2.26M	0.06%	328

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palisade Capital Management's HZNP Position: Q4 2016 in Review

Palisade Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 119,350 shares — an estimated $2.16M sold.

Palisade Capital Management first reported a position in HZNP in Q4 2014 and held it in 4 quarters. The position peaked at $9.76M in Q2 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

Palisade Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
Palisade Capital Management sold 119,350 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $2.16M.
Palisade Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 4 quarters.
Palisade Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.76M in Q2 2015.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.